|Bid||79.90 x 1000|
|Ask||81.75 x 800|
|Day's Range||79.00 - 81.81|
|52 Week Range||32.95 - 90.19|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Shareholders in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had a terrible week, as shares crashed 23% to US$67.10 in...
Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are plummeting today, down by 22% as of 1:35 p.m. EST, after the biotech released data from a mid-stage study of etrasimod in patients with atopic dermatitis, commonly called eczema. The good news is that there are some hints that etrasimod might be helping patients with eczema. Using that measurement, there wasn't a statistical difference between either of the two dose levels of etrasimod compared to a placebo after 12 weeks of treatment.